Day: November 22, 2019

NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICESCARLSBAD, Calif., Nov. 22, 2019 (GLOBE NEWSWIRE) — Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) announces financial results for the three and nine months ended September 30, 2019.To our Shareholders:Q3 2019 was a watershed quarter for the Company and served to sharpen our strategic direction as we prepare for 2020 and the longer term. In the last 2 quarters, we have seen a rapid acceleration of sales in what we call third-party products; those products we in-license from other vendors in order to meet the needs of surgeons, both new surgeons and those we currently we work with and their patients. Third-party products, when used in conjunction with Aurora products may serve to enhance our sales but they may also act to displace...

ATHENS, GREECE, Nov. 22, 2019 (GLOBE NEWSWIRE) — TOP Ships Inc. (the “Company”), an international owner 2nd operator of modern, fuel efficient “ECO” tanker vessels, announced today that it closed the previously announced two Financing Agreements with a major Chinese Financier, for total gross proceeds of $45.8 million, in relation to the 50,000 dwt product/chemical tankers M/T Stenaweco Energy and M/T Stenaweco Evolution. The proceeds were used towards the reacquisition of the two vessels via the exercise of purchase options. The Company paid $47.9 million for the exercise of both purchase options and the term of both facilities is 10 years. Evangelos Pistiolis, the President, Chief Executive Officer and Director of the Company, said:“We are very pleased to have concluded these new financings that we expect will improve...

SAN DIEGO, Nov. 22, 2019 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that it has extended its collaboration agreement with GlaxoSmithKline plc (GSK), one of the world’s leading healthcare companies, to raise awareness of the importance of timely diagnosis of systemic lupus erythematosus (SLE), the most common and severe form of lupus. At the center of the program are the proprietary AVISE laboratory tests, which can facilitate early diagnosis and management of SLE, a complex, incurable autoimmune disease. The details of the agreement are confidential.This extension follows a similar one-year extension...

GAITHERSBURG, Md., Nov. 22, 2019 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced updated results from the interim analysis of its Phase 2 clinical study evaluating the safety and immunogenicity of the company’s chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate across a series of dosing regimens. The interim analysis has shown that after the first dose is administered, up to 98% of study participants produced a neutralizing antibody response against the chikungunya virus (CHIKV) within seven days after vaccination. Further, the immune response persisted for at least one year for subjects who received a single dose. The presentation was made at the American Society of Tropical Medicine and Hygiene (ASTMH) annual meeting in Maryland being held November 20 to 24, 2019.Abbey Jenkins, senior vice president...

Nasdaq OMX Copenhagen A/SCompany announcement no. 469November 22, 2019Glunz & Jensen Holding A/SGlunz & Jensen Holding A/S announces the H1 2019/20 reporting in attached. (Reposted)For further information please contact:CEO Martin Overgaard Hansen phone +4522608405Chairman of the Board of Directors Flemming Nyenstad Enevoldsen, phone +4540431303AttachmentOMX_469 H1_2019_20 company announcement

News release from Vestas Northern and Central EuropeHamburg, 22 November 2019Vestas has secured an order from Fu-Gen AG, a Swiss developer for the 42 MW wind project Fjällboheden northwest of Skellefteå in Northern Sweden. To maximise the project’s power production in the site’s cold climate, Vestas provides ten V150-4.2 MW turbines equipped with the Vestas Anti-Icing System, which efficiently minimises ice formation on blades.“This project is a major first milestone for Fu-Gen and its partner Abraxas Capital Management in the Swedish market. We are delighted to have Vestas as the supplier of turbines and of the AOM service agreement and look forward to a fruitful cooperation for the future”, says Matthias Rapp, Chairman of Fu-Gen AG.“With the Fjällboheden project, Vestas once again demonstrates the ability to offer wind energy solutions...

Polarcus Limited (“Polarcus” or the “Company”) (OSE: PLCS) announces the award of an XArray marine seismic acquisition project in Malaysia commencing late December 2019 with a duration of approximately 4 months.Following this award, the Polarcus core fleet is fully booked to early Q2 2020. ContactsHans-Peter Burlid, CFO+971 50 559 8175hp.burlid@polarcus.comLars Oestergaard, COO+971 54 791 0564lars.oestergaard@polarcus.comAbout Polarcus

SUNNYVALE, Calif., Nov. 22, 2019 (GLOBE NEWSWIRE) — Juniper Networks (NYSE: JNPR), a leader in secure, AI-driven networks, today announced it has achieved an industry-first with the completion of a successful field trial delivering 400Gbps Ethernet live traffic over 1,300 miles. The trial was conducted in conjunction with SCinet, the Supercomputing 2019 Conference’s high-capacity network. SCinet used Juniper’s PTX10003 Packet Transport Router to deliver unprecedented capacity, flexibility and programmability.This field trial marks an important step toward progressing the transition to 400GbE network capacity, which is vital to support bandwidth demands from advanced high-performance computing, next-generation cloud data center architectures, emerging 5G networks, augmented and virtual reality and 4K video production and distribution....

CAMBRIDGE, Mass., Nov. 22, 2019 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced detailed results from the Phase 3 EVOLVE-MS-2 study demonstrating the improved patient-assessed gastrointestinal (GI) tolerability of VUMERITY™ (diroximel fumarate), a new FDA-approved treatment for relapsing forms of multiple sclerosis (MS), compared to TECFIDERA® (dimethyl fumarate). These EVOLVE-MS-2 results are being presented at the 27th Annual Meeting of the European Charcot Foundation in Italy (Nov. 21-23).  “We know that each patient’s journey can vary greatly in MS, so Biogen aims to meet individual treatment goals through our broad MS portfolio,” said Alfred Sandrock, Jr., M.D., Ph.D., Executive Vice President, Research and Development, and Chief Medical Officer at Biogen. “TECFIDERA is a clinically meaningful treatment for patients,...

TORONTO, Nov. 22, 2019 (GLOBE NEWSWIRE) — Alamos Gold Inc. (TSX:AGI; NYSE:AGI) (“Alamos” or the “Company”) today announced that the Company’s Board of Directors has declared a quarterly dividend of US$0.01 per common share. This represents the Company’s 10th consecutive year of paying a dividend during which time the Company has returned $156 million to shareholders through dividends and share buybacks.The dividend is payable on December 20, 2019 to shareholders of record as of the close of business on December 6, 2019. This dividend qualifies as an “eligible dividend” for Canadian income tax purposes.About AlamosAlamos is a Canadian-based intermediate gold producer with diversified production from four operating mines in North America. This includes the Young-Davidson and Island Gold mines in northern Ontario, Canada and the Mulatos...